Watching MEI Pharma; Hearing Brookline Capital Reiterates Buy Rating, $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital has reiterated its Buy rating for MEI Pharma, maintaining an $80 price target.
May 23, 2023 | 3:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MEI Pharma's Buy rating has been reiterated by Brookline Capital, with an $80 price target.
Brookline Capital's reiteration of the Buy rating and $80 price target for MEI Pharma indicates a positive outlook for the stock. This news is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100